Member Info for JimiHendrix

Well if the share price drops to 0.2 or so tomorrow the major shareholders will have an opportunity to buy a ton more shares cheap before the dilution and be in a position to influence the future of the company.

They’ve not even mentioned CYP2C19 NHS commissioning, just that they expect initial international sales next year. Really appalling. They mentioned twice before that they’re carefully balancing what they reveal to the market so as to not give the competitor an advantage (or words to those affect).

Right thanks I see it, I was relying on ChatGPT to find it and it couldn’t for some reason.

What would be useful is to know why it’s changed since June presentation and why they didn’t mention it in the trading update. My instinct was correct, just a shame the company is so flipping dishonest.

Where does it say this “they also said it wont break even until FY27” ? …I can’t find that anywhere.

Where does it say this?

“ Directors taking 10% salary deferral - far too late

Now saying they wont be EBITDA positive until end FY 2027 (ie June 2027)”

Yep! I think it’s daylight robbery, there’s been some serious deception recently from the company. I wonder if they have any idea what they’re doing to some private investors, the financial destruction they cause, or perhaps the directors think that everyone sees AIM as just a bit of fun. The presentation from June is now looking incredibly misleading.

It might mean that labs will be buying that one and then the result being genedrive has the whole uk market rather than just POC. Not sure, but it’s strange that they’ve always been about point of care. Seems like a change in strategy perhaps.

Shocking discount! This bits interesting… “and translation of IP to include a laboratory platform CYP2C19 genotyping assay in addition to point of care.”

Could be large buy orders they’ve been asked to fill at 0.55 or 0.5 perhaps.

Maybe there will be a bidding war between David and Robert? Or they may be forming a concert party.

I’m not sure John’s mid - late September prediction for the guide came from NICE at all. I also received the email from the NICE lady about lack of budget etc and that was a couple of weeks after, and in that she made it clear that NICE weren’t aware of any timeframes.

My own estimate of late August was based on previous NHS pilots, but this one appears not to have followed the same timeline as those.

Personally I don’t know what to expect over the coming weeks now. I can’t imagine Peel advising the company to take David’s alternative funding offer as placings are one of the ways they make money.

I think it just gives them the ability to raise below 1.5p and to issue more shares. I’m not sure we’ll see anything change, until the fundraise when the total share count will increase.

I think they’ll receive some revenue from a few new sites here and there, and from the phased Scotland rollout. Potentially EU / ME sales early 2026 but I’m not expecting anything significant until after April. I’m not ruling it out though! It just feels like 50/50 at the moment to me, who knows what’s going to happen in the near term.

ChatGPT is just weighing up the evidence we can see, o who knows what’s going on behind the scenes.

Short answer: it’s probably de-prioritised, not abandoned.

Why ChatGPT thinks that:

• System upheaval + tight in-year budgets. NHSE’s 2025/26 guidance pushes systems to “live within their means,” minimise ring-fencing, and cut costs, while ICB structures and roles are being reworked. In that climate, new national roll-outs without in-year funding tend to slip down the queue. 

• Guidance without budget still has value but less urgency. NICE DG59 is already public (so the clinical what/why exists). An NHSE implementation guide mainly adds the how/when/who pays. If “who pays” is effectively next April (start of the new financial year), publishing now is less critical from NHSE’s perspective. 

Why it could still come before April:

• Some centres may self-fund or use procurement routes like the NHS Supply Chain MedTech DPS, and an NHSE guide would smooth that path. (DPS is live and positioned for innovation purchasing.) 

• Quality infrastructure is spinning up (EMQN’s new CYP2C19 POCT EQA scheme), which usually complements national guidance and early adoption.

Taking this with a pinch of salt but ChatGPT’s opinion on the implementation guide in light of the email from NICE about budget, the delay, the mention about POC funding pathway from next April and NHSE restructuring is…

ChatGPT’s read overall:

• Priority now: medium-low until the 2026/27 (from April 2026) funding position is settled; NHSE teams are busy with structural changes and cost controls.

• Most likely pattern: toolkit published close to or with the new-year funding/governance updates, so systems can act the moment budgets open.

Both tests have been on the NHS Supply Chain’s DPS for several months according to my notes, so nothing new unfortunately.

This makes the process easier for hospitals to adopt, like a pre approved list of tests. It’s not a funding pathway though, which is what is needed for CYP2C19. We’ll probably need to wait until April for the POC national funding pathway to go live, going by what was said in the trading update.

They mentioned in the reorganisation RNS that they may need to call another GM later to get fresh authority to issue more shares.

Unless longer-term financing is secured, the company is likely to seek additional authority to allot shares and disapply pre-emption rights at a further general meeting.

I’m not sure which news they could announce. Perhaps acknowledging the Scotland rollout but we know that. The company can’t suddenly release news of say implementation guide unless they’re in cahoots with the NHS, which I’d imagine would breaking various AIM rules.

Could there be other sales news held back until after a placing? Possibly, but I’m doubting it.

Will check their last presentation for expected near term news items.

1st January Stephen but think there’s zero chance of EBITDA positive then. The only hope imo is around May, but that’s only if they get national commissioning for CYP2C19, which sounds like it could happen but not until after the new funding pathway for POC devices goes live next April.